Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.
Type:
Application
Filed:
October 30, 2012
Publication date:
May 16, 2013
Applicants:
Allon Therapeutics Inc., Ramot at Tel-Aviv University Ltd.
Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.
Type:
Grant
Filed:
February 18, 2010
Date of Patent:
December 4, 2012
Assignees:
Ramot at Tel-Aviv University, Ltd., Allon Therapeutics, Inc.
Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.
Type:
Grant
Filed:
October 3, 2008
Date of Patent:
March 27, 2012
Assignees:
Ramot at Tel-Aviv University, Allon Therapeutics, inc.
Abstract: This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an acetylcholinesterase inhibitor. Multiple sclerosis is treated by a combination of an ADNF III polypeptide and glatiramer acetate. Schizophrenia is treated with a combination of an ADNF III peptide and an antipsychotic drug, selected from Aripiprazole, Clozapine, Ziprasidone, Resperidone, Quetiapine, and Olanzapine.
Type:
Application
Filed:
June 30, 2011
Publication date:
January 12, 2012
Applicants:
ALLON THERAPEUTICS INC., Ramot at Tel Aviv University Ltd.
Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.
Type:
Application
Filed:
February 18, 2010
Publication date:
August 26, 2010
Applicants:
Ramot at Tel-Aviv University Ltd., Allon Therapeutics Inc.
Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.
Type:
Application
Filed:
October 3, 2008
Publication date:
May 28, 2009
Applicants:
Ramot at Tel-Aviv University, Allon Therapeutics, Inc.
Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.
Type:
Application
Filed:
March 23, 2006
Publication date:
November 2, 2006
Applicants:
Ramot at Tel-Aviv University Ltd., Allon Therapeutics, Inc.